menu
    • menu
    [{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Undisclosed"},{"orgOrder":0,"company":"ThirtyFiveBio","sponsor":"Mayewell Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"ThirtyFiveBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ThirtyFiveBio \/ Mayewell Capital","highestDevelopmentStatusID":"4","companyTruncated":"ThirtyFiveBio \/ Mayewell Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by ThirtyFiveBio

    Menu

    ThirtyFiveBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ThirtyFiveBio

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ThirtyFiveBio

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Mayewell Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ThirtyFiveBio Closes Bridge Round Backed by AbbVie Ventures

                            Details : The funds will support the continued development of the company's first-in-class GPR35 inhibitor program, which is currently advancing through preclinical development of Ulcerative Colitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 15, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Mayewell Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ThirtyFiveBio

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ThirtyFiveBio

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ThirtyFiveBio Wins Grant to Advance GPR35 Inhibitor for Ulcerative Colitis

                            Details : The funding will support ThirtyFiveBio in developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 for the treatment of gastrointestinal diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Innovate Biopharmaceuticals

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ThirtyFiveBio

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            ThirtyFiveBio

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ThirtyFiveBio Emerges From Stealth with Presentation of First Data from GPR35 Antagonist Program at American A...

                            Details : A small molecule inhibitors of G protein-coupled receptor 35 (GPR35) which has the potential to drive pro-oncogenic growth biology for the treatment of gastrointestinal (GI) system cancers.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 30, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth